Using Proton Pump Inhibitors is not Associated With Adverse Outcomes in Patients With Chronic Myeloid Leukemia Treated With Dasatinib

Clin Lymphoma Myeloma Leuk. 2024 Jul;24(7):484-487. doi: 10.1016/j.clml.2024.02.014. Epub 2024 Feb 29.

Authors

Fadi G Haddad¹, Cedric Nasnas², Koji Sasaki², Shilpa Paul², Ghayas C Issa², Caitlin Rausch², Elias Jabbour², Hagop Kantarjian²

Affiliations

¹ Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address: [email protected].
² Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.

PMID: 38503634
DOI: 10.1016/j.clml.2024.02.014

No abstract available

Keywords: Antacid; H2 blocker; Response; Tyrosine kinase inhibitor.

Publication types

Letter

MeSH terms

Adult
Aged
Antineoplastic Agents / adverse effects
Antineoplastic Agents / therapeutic use
Dasatinib* / adverse effects
Dasatinib* / therapeutic use
Female
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive* / drug therapy
Male
Middle Aged
Protein Kinase Inhibitors / adverse effects
Protein Kinase Inhibitors / therapeutic use
Proton Pump Inhibitors* / adverse effects
Proton Pump Inhibitors* / therapeutic use
Treatment Outcome

Substances

Dasatinib
Proton Pump Inhibitors
Protein Kinase Inhibitors
Antineoplastic Agents